Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers.
about
Genetically delivered antibody protects against West Nile virusA current perspective on applications of macrocyclic-peptide-based high-affinity ligandsPassive immunization against HIV/AIDS by antibody gene transfer.Neural cell adhesion molecule 2 as a target molecule for prostate and breast cancer gene therapy.Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transferAAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors.Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein.Synergistic effect of a tissue kallikrein 1 and tissue inhibitor of matrix metalloproteinase 1 co‑expression vector on the proliferation of rat vascular smooth muscle cells.Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy.Gene therapy of gynaecological diseases.Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge.Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeysGene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2.Challenges in monoclonal antibody-based therapies.Adenoviral vector-based strategies for cancer therapy.In situ production of therapeutic monoclonal antibodies.State of play and clinical prospects of antibody gene transfer.Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.Adenovirus-Vectored Broadly Neutralizing Antibodies Directed Against gp120 Prevent Human Immunodeficiency Virus Type 1 Acquisition in Humanized Mice.Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge.Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies.
P2860
Q27485481-26208982-0985-4B6B-98FC-4C7899968F47Q28072407-4DAFB103-F774-4CD7-8C66-1F1BB1279565Q30358434-FC7721E9-828F-4E77-A650-F67283C4124DQ33788355-7FB6F518-0386-4A45-9FC4-494DD5F586ADQ34005560-26E25486-6C8B-40BD-A334-B20B7ADDC673Q34063390-842ADB1E-1AF6-46CF-9CD3-1CAAD13EE2EDQ34110625-29D3C7F7-A8CE-46F8-8EF8-6D5B18F42611Q36089841-B302FDD6-3345-4E71-AE1B-4632A9D756F3Q36715285-0606605E-64B0-4911-96F3-D8474D894614Q36922247-DEDDFAFC-FC5E-44A1-8FED-0982A6985735Q37145022-EC60FEBE-61BE-4391-B8C8-3EFD25A252C4Q37295534-4BE8C40E-F473-436E-A8D1-7FEBEB7A6FDCQ37393751-F5029F09-FB4F-4095-8C1B-91BA7E9B0937Q37398725-A906DF67-FC68-414F-8537-FA24061E3116Q37409025-94FABA59-8228-4F70-9CA3-2F240C39ABE8Q38314210-228AF664-B1B4-4453-A0CE-8B9692A09120Q38737706-08724413-6F9D-4AE5-A4A1-CC2826601ACBQ38753004-3F487D59-381C-494C-AAAF-DF86F11AD0AAQ41249890-00968D9B-938B-4A95-A0A9-DA203551824AQ41434430-431F370A-FD84-4ECB-ABC4-336AB4DA044CQ55241055-551FDF48-305E-4938-8EB1-F7D4BA878C23
P2860
Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Gene therapy using adenovirus- ...... HER-2 overexpression cancers.
@en
type
label
Gene therapy using adenovirus- ...... HER-2 overexpression cancers.
@en
prefLabel
Gene therapy using adenovirus- ...... HER-2 overexpression cancers.
@en
P2093
P921
P1476
Gene therapy using adenovirus- ...... HER-2 overexpression cancers.
@en
P2093
Changqin Su
Jonathan Sham
Mengchao Wu
Minggao Guo
Minghong Jiang
Qijun Qian
Wenfang Shi
Xinhua Wang
P304
P356
10.1158/1078-0432.CCR-06-0746
P407
P433
P577
2006-10-01T00:00:00Z